J&J: Getting Paid Up-Front for New Technology
Executive Summary
The story of the successful development by Cordis Corp., a Johnson & Johnson operating company, of the first drug-eluting stent, the Cypher, and its introduction this year into the US market has been well chronicled. What is not as well known is the equally successful and ground-breaking work that Cordis did in obtaining incremental reimbursement (an increase over the existing reimbursement level for bare metal coronary stents) for the Cypher stent from Medicare prior to the device receiving FDA approval. This is an interview with the person who directed Cordis' reimbursement efforts for the Cypher stent, Brian Firth, MD, PhD, VP for medical affairs and health economics, who explains how Cordis developed and implemented its reimbursement strategy for Cypher, and the implications of this approach for future new technologies.
You may also be interested in...
Cypher’s Impact On Regulatory, Reimbursement Landscape
During its rise and fall as the first device on the “blockbuster” drug-eluting stent market, Cordis' Cypher sirolimus-eluting coronary stent helped break new ground on both regulatory and reimbursement fronts.
Cypher’s Impact On Regulatory, Reimbursement Landscape
During its rise and fall as the first device on the “blockbuster” drug-eluting stent market, Cordis' Cypher sirolimus-eluting coronary stent helped break new ground on both regulatory and reimbursement fronts.
Parallel FDA/CMS Review Is Poised for Prime Time - But Is Anybody Biting?
The device industry has long complained about the lengthy, separate review times required to achieve FDA and CMS clearance. Finally, the two agencies are working together on a pilot program to make this process faster and more efficient. Industry's response: not so fast. Despite the apparent advantages parallel review can offer to product companies, industry has been cautious and slow to respond out of concern for protecting proprietary data and the possible need for more complex clinical studies. Parallel review may represent an example of regulators being ahead of industry in streamlining the regulatory process, and the burden will be on FDA and CMS to demonstrate the true value of this approach.